

US firm offers 99% discount on Hep-C drug

Mumbai: Amid mounting criticism over the eye-popping price of Sovaldi, the first breakthrough treatment for hepatitis C virus, US pharma firm Gilead Sciences has offered to introduce the drug in India at nearly 99% discount on the US price.

The drug will cost about \$900 (around Rs 54,000) in India for a 12-week course of treatment, a fraction of the \$84,000 (over Rs 50 lakh) price for the same treatment in the US. Gilead Sciences will adopt a tiered pricing structure here, like the one for HIV treatment in developing countries like India. TNN

For the full report, log on to www.timesofindia.com

Pricing.